Ac immune reports first quarter 2024 financial results and provides a corporate update

Ac immune reports first quarter 2024 financial results and provides a corporate update landmark deal announced with takeda for aci-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billion aci-24.060 abate phase 2 trial on track to report abeta-pet imaging results in q2 2024, evaluating amyloid plaque reduction after 6 months of anti-abeta active immunotherapy aci-7104.056 vacsyn phase 2 trial of anti-a-syn active immunotherapy in parkinson's disease (pd) on track for safety and immunogenicity interim data in h2 2024 three-year cash runway with chf 104.8 million at quarter end, plus $100 million upfront from takeda and the anticipated aci-35.030-related chf 25 million milestone lausanne, switzerland, may 13, 2024 – ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the quarter ended march 31, 2024, and provided a corporate update. dr. andrea pfeifer, ceo of ac immune sa, commented: “we are thrilled to have announced today our agreement with takeda to advance aci-24.060 anti-abeta active immunotherapy in alzheimer's disease (ad).
ACIU Ratings Summary
ACIU Quant Ranking